Objectives: To investigate possible associations between 25-hydroxyvitamin D 3 (25(OH)D 3 ), oestradiol (E 2 ) and IFN-gamma (IFNc) in female patients with inactive systemic lupus erythematosus (SLE). Methods: Female patients with inactive SLE and age-matched healthy controls were recruited into this cross-sectional study. Serum concentrations of 25(OH)D 3, E 2 and IFNc were measured by radioimmunoassay with gamma-counters and enzyme-linked immunosorbent assay. Results: 36 patients and 37 controls were enrolled. In patients with SLE, the concentration of 25 (OH)D 3 was lower and E 2 was higher compared with controls. In vitamin D deficient (i.e., 25 (OH)D 3 20 ng/ml) patients, IFNc was 150% higher compared with patients with 25(OH) D 3 >20 ng/ml and controls. The concentration of E 2 was higher in all patients compared with controls independently of the vitamin D level. A difference was found between patients and controls in the correlation of 25(OH)D 3 with E 2 and a positive correlation was found between E 2 and IFNc in all participants. Conclusions: Our results suggest that E 2 may have a strong modulating effect on vitamin D function which is significant only at low concentration of E 2 .
Introduction
Systemic lupus erythematosus (SLE) is a complex systemic autoimmune disease and involves the loss of tolerance to nuclear selfantigens, immune complex formation and chronic inflammation. 1 The pathogenesis of SLE consists of a complex of cross-talk mediated by cytokines that orchestrate immune cell interactions. 2 Studies have shown that interferon gamma (INFc) plays an important role in the development and severity of SLE. 3 In humoral immunity, IFNc stimulates B-cell activation to induce immunoglobulin secretion, while an in cellmediated immune response from IFNc directs differentiation of T cells to a Th1 phenotype. [4] [5] [6] The vitamin D status of an individual depends on access to vitamin D through dietary intake and epidermal synthesis from ultra-violet (UV) light exposure. Importantly, vitamin D reduces the risk for several diseases including severe infections, cancer and autoimmune rheumatic diseases because it regulates both innate and adaptive immunity. 7 Studies have demonstrated vitamin D receptor (VDR) expression in both T-and B-lymphocytes. 8 In addition, 1,25-hydroxy vitamin D 3 (1, 25 [OH] 2 D 3) has been shown in vitro to inhibit the action of cytokines produced by Th1 immune cells. 9 Moreover, a direct effect of 1,25(OH) 2 D 3 on B-cell homoeostasis has recently been confirmed. 10 Therefore, vitamin D may have a role in B-cell-related autoimmune disorders such as SLE.
Reports suggest that patients with SLE have alterations in steroid hormone metabolism. 11 It has been demonstrated that oestrogen effects are probably mediated through oestrogen receptors a and b, which are expressed in a wide range of immune cells and are involved in innate and adaptive immune responses. 12 Oestrogens have specific effects on T and B cell maturation, dendritic cells and peripheral blood mononuclear cells. 13 They also cause rapid maturation of B cells in bone marrow where they cause auto-reactive B cell deletion to become less efficient. 14 In a previous study in females of childbearing age with inactive SLE, an association between vitamin D, oestradiol (E 2 ), and IFNc was not completely established. 15 Therefore, the aim of this study was to clarify the relationship further.
Methods
This was a cross-sectional study which conformed to recommendations by the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE). 16 Blood samples were taken from all participants in the morning between 7:00 and 8:00. Antinuclear antibodies (ANA), antidouble-stranded DNA (anti-dsDNA), antiSmith (anti-Sm), parathyroid hormone (PTH) and complement components C3, and C4, were measured in patients with SLE. Reference values were: ANA-negative U/ml; anti-dsDNA >40 IU/ml; antiSm >40AU/ml; complement C3 (0.9-1.8 g/L) and C4 (0.1-0.4 g/L). Complement components were determined using a laser nephelometry (ProSpec nephelometer, Dade Behring, Siemens Healthcare Diagnostics, Liederbach, Germany).
Circulating levels of 25(OH)D 3 provide a direct reflection of vitamin D status. 19 Serum concentrations of 25(OH)D 3 were measured in samples from all participants using radioimmunoassay (RIA) and a gamma-counter (DIA source Immunoassays, Louvain-laNeuve, Belgium catalogue number KIP 1961; P. I. Number 1700543/en; Revision nr.:130729/1). Intra-assay variation was 8.7% and inter-assay variation was 7.3%. Vitamin D deficiency was defined as <20 ng/ml, insufficiency was 21-29 ng/ml and normal range was 30-80 ng/ml. 19 Serum concentrations of E 2 were also measured using RIA and gamma-counter and intra-assay variation was 6.3%, and interassay variation was 10.3%. Oestrogen status was assessed from samples taken from the 3rd-5th day of the menstrual cycle. Reference values for E 2 were between 0.11-0.65 nmol/L. Levels of IFNc was determined using a commercially available enzyme-linked immunosorbent assay (ELISA) kit (eBioscience, San Diego, CA, USA) which had a detection limit of 0.99 pg/ml.
Statistical analyses
Sample size was estimated using PASS software (Release 11, NCSS, LLC. Kaysville, Utah, USA; 2011). Using a standard deviation (SD) of 2.08 ng/ml for the concentration of 25(OH)D 3 with a=0.05 and 1-b, it was estimated that 36 patients with SLE were required for the study. 15 Statistical analyses were performed using PASS software (Release 11, NCSS, LLC. Kaysville, Utah, USA; 2011) and P < 0.05 was taken to indicate statistical significance.
Differences in serum 25(OH)D 3 , IFNc, and E 2 between patients and controls were analysed using the Mann-Whitney U test and area under the curve (AUC) was used as the measure of standardized effect together with absolute and relative median differences. Differences between four groups (i.e., low and high levels of vitamin D in patients and controls) were analysed using the Kruskal-Wallis test. Statistical significance from post-hoc tests were corrected by the Holm-Bonferroni method. Correlations between numeric variables were analysed using Spearman's rank correlation. Cut-off values for serum 25(OH) D 3 , IFNc, and E 2 were determined using Receiver Operating Characteristic (ROC) curve analysis and Youden's index J. The independent association of serum 25(OH) D 3 , IFNc and E 2 levels with SLE was assessed using multivariate binary logistic regression.
A measurable increase in SLE disease activity in one or more organ systems involving new or worse clinical signs and symptoms and/or laboratory measurements was deemed an SLE flair. 20 The moderating effect of serum E 2 on the association of serum 25(OH)D 3 and SLE flair was analysed using "Process" release 2.12 (Andrew F. Hayes, Ohio State University, 2014). 21 Serum E 2 values defining the region of a significant association between serum 25 (OH)D 3 and SLE flair were assessed by the Johnson-Neyman technique as implemented in "Process". 21 Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using a multivariate, binary logistic regression model to determine the disease characteristics associated with vitamin D deficiency, IFNc and E 2 levels.
Results
In total, 36 female patients with inactive SLE and 37 age-matched healthy controls were included in the study. Demographic and clinical characteristics of the participants are shown in Table 1 . The median value of 25(OH)D 3 was statistically significantly lower in patients with SLE compared with controls (P ¼ 0.001), while the median values for IFN-c and E 2 were statistically significantly higher in patients with SLE compared with controls (P < 0.001).
Participants were further divided into two groups based on 25(OH)D 3 levels (i.e., 20 ng/ml and >20 ng/ml). In the control group, there were no differences in IFN-c, E 2 , and PTH between participants with 25(OH)D 3 20 ng/ml or >20 ng/ml and so data were combined and compared with the two SLE subgroups ( Table 2) . Patients in 25(OH)D 3 20 ng/ml sub group had statistically significantly higher levels of IFNc compared with patients in the 25(OH) D 3 >20 ng/ml sub-group or control group (P < 0.001). Both the 20 ng/ml and >20 ng/ml 25(OH)D 3 sub-groups of patients had statistically significantly higher levels of E 2 than the control group (P ¼ 0.009 and P ¼ 0.035, respectively) .
For all participants, the correlation between E 2 and IFNc was positive and At low levels of E 2 (i.e., 0.27 mmol/l; 10th percentile), the association between 25(OH)D 3 and SLE flair was statistically significant (P=0.002) (Figure 1) . The higher the 25(OH)D 3 , the lower the probability for SLE flair in patients with low E 2 levels. However, at high values of E 2 the association between 25(OH)D 3 and SLE flair was not statistically significant. The Johnson-Neyman technique showed that the association between 25(OH)D 3 and SLE flair was statistically significant 
Discussion
This study was designed to investigate the association between vitamin D, E 2 and IFN-c in female patients with inactive SLE. Vitamin D is an important hormone with immunomodulatory properties and has a vital role in many biological and biochemical pathways. [22] [23] [24] It has been suggested that UV exposure may catalyse symptom exacerbation or flare events in patients with SLE. 25, 26 As a consequence, patients are often advised to adopt sun protective measures and use both physical and chemical barriers routinely ad these measures may result in vitamin D deficiency. 26 Indeed, many patients with SLE have been found to have a deficiency in 25(OH)D 3 . 27 Interest in the association between 25 (OH)D and systemic SLE began in the early 2000's following observations that vitamin D levels were associated with low bone mass in patients with SLE. 28 Lack of sun exposure and use of hydroxychloroquine (HCQ) was thought to be responsible for the low vitamin D levels in these patients. 29 Following these initial findings, several more studies confirmed the association between SLE and 25(OH)D. 27, 30, 31 Several studies have now shown a positive association between disease activity and vitamin D deficiency in patients with SLE. [32] [33] [34] In addition, one study found a negative correlation between the serum concentration of vitamin D and disease activity which suggests a possible protective role for vitamin D in SLE. 33 However, data from a randomized, placebo-controlled, clinical trial involving 90 patients with Vitamin D-deficient SLE showed that vitamin D supplementation did not affect disease activity. 35 Data from this present study, in female patients with inactive SLE showed that their blood levels of vitamin D were lower compared with healthy controls. In accordance with our previous findings, we also found that patients with low levels of vitamin D (i.e., 25(OH)D 3 20 ng/ml) had a 7.6 times higher risk for the development of SLE flair compared with patients with higher levels of vitamin D (i.e., 25(OH) D 3 > 20 ng/ml). 15 These results suggest a beneficial effect of vitamin D on disease activity.
The importance of IFNc in the pathogenesis of lupus was highlighted by a study in lupus mice that found accelerated disease in mice receiving IFNc or its inducers, while those receiving anti-IFNc antibodies had a significantly delayed onset of disease. 36 The ability of IFNc to promote B cell autoantibodies and activate IgG Fc receptors and complement may also contribute to disease severity. 37 This present study showed that levels of IFNc were higher in patients with inactive SLE compared with controls. In addition, in patients with low levels of vitamin D (i.e., 25(OH)D 3 20 ng/ml), IFNc was 150% higher than patients with higher levels of Vitamin D (i.e., 25(OH)D 3 > 20 ng/ml). Furthermore, the risk of an SLE flair was almost 10 times higher in patients with IFNc >1.3 pg/ml compared with patients with IFNc 1.3 pg/ml. These results emphasize the importance of cytokine balance in SLE. 38 However, studies examining the role of IFNc in SLE have been contradictory. Some have found a correlation between serum IFN-c level and disease activity and a correlation between IFNc expression and severity of lupus nephritis while others show decreased IFNc levels in lupus nephritis. 39, 40 Nevertheless, monoclonal antibodies targeting IFNc are being investigated for the treatment of SLE. 41 Oestrogens are considered immunomodulating hormones. 42 One study suggested that E 2 may promote innate immunity by enhancing production of IFNc from CD11c(þ) cells. 43 Others studies have proposed that E 2 has a direct effect on the production of immunoglobulin (Ig) G antidsDNA antibodies as well as total IgG in peripheral blood mononuclear cells from patients with SLE. 44, 45 However, opinions differ about the influence of disease activity on ovarian function. Some studies have found a relationship between SLE activity and menstrual cycle disturbances, while others have failed to confirm an association. [46] [47] [48] [49] In the present study, the risk of a flair was 5.4 times higher in patients with E 2 >0.345 nmol/L compared with those with E 2 0.345 nmol/L. Our results also showed a positive correlation between E 2 and IFNc and a difference in the correlation between 25(OH)D 3 and E 2 in patients and controls. These findings suggest an interaction between 25(OH)D 3 and E 2 with regard to the probability of SLE reactivation. Interestingly, at low concentrations of E 2 , the association between 25 (OH)D 3 and SLE flair was statistically significant but the association was not significant at high concentrations of E 2, . We hypothesise that the conditional association between 25(OH)D 3 with SLE flair at different values of E 2 suggests a possible pro-inflammatory effect of oestradiol. Furthermore, these findings suggest that vitamin D may lose a protective effect at higher oestrogen levels. Since Vitamin D and oestrogen act via receptors on immune cells, 50, 51 including B lymphocytes which are important in the pathogenesis of SLE, we suggest that competition for receptor sites or an altered postreceptor response could explain this proposed effect. In accordance with this suggestion is the observed beneficial effects of anti-oestrogens, such as tamoxifen, in patients with SLE. 52 It is interesting that vitamin D and oestradiol appear to have an interwoven action in SLE. Several studies have shown that the active form of vitamin D, calcitriol, regulates the expression of aromatase. [53] [54] [55] In addition, in young women both progesterone oestrogen levels decreased after 4 weeks of vitamin D supplementation . 56 Our study had several limitations. For example, the sample size was small and the study had a cross-sectional design. More longitudinal research is needed to determine the validity of the crosssectional associations between 25(OH)D 3 and E 2 observed in this study. In addition, to maintain homeostasis in patients with SLE, an evaluation of hormone and cytokine status should be considered. A better understanding of the hormonal and cytokine status in patients with SLE may lead to future strategies for disease prevention. Furthermore, more studies are required in patients with inactive SLE using high doses of vitamin D for long periods. 57 In conclusion, a positive correlation was found between E 2 and IFNc in all participants and a difference was observed between patients and controls in the correlation of 25(OH)D 3 with E 2. Furthermore, we observed a significant interaction between vitamin D and E 2 with regard to the probability of SLE flair. Our results suggest that oestrogens have a strong modulatory effect on vitamin D function, and this dual effect has a protective effect on SLE flair only at low oestrogen levels. Based on our results, we suggest that vitamin D supplementation may be useful in SLE patients.
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